Showing results (1251-1260 of 1,376) with videos related to

Sort By:
Pageof 138
Neurology|February 1, 1997
Surgical treatment of patients with single and dual pathology: relevance of lesion and of hippocampal atrophy to seizure outcomeL M Li, F Cendes, C Watson, et al.
Neurology and Therapy|July 24, 2024
Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)Heinz Wiendl, John Foley, Gilles Defer, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 14, 2018
Physical activity and dentate gyrus volume in pediatric acquired demyelinating syndromesGiulia Longoni, Robert A Brown, Berengere Aubert-Broche, et al.
Critical Reviews in Toxicology|February 12, 2014
Diuron-induced rat urinary bladder carcinogenesis: mode of action and human relevance evaluations using the International Programme on Chemical Safety frameworkMitscheli Sanches Da Rocha, Lora L Arnold, Maria Luiza Cotrim Sartor De Oliveira, et al.
The Lancet. Neurology|September 8, 2019
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trialJeffrey A Cohen, Giancarlo Comi, Krzysztof W Selmaj, et al.
The New England Journal of Medicine|September 13, 2018
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple SclerosisTanuja Chitnis, Douglas L Arnold, Brenda Banwell, et al.
The Lancet. Neurology|September 8, 2019
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trialGiancarlo Comi, Ludwig Kappos, Krzysztof W Selmaj, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 29, 2022
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trialBruce Ac Cree, Krzysztof W Selmaj, Lawrence Steinman, et al.
Molecular Plant Pathology|June 24, 2010
Location and activity of members of a family of virPphA homologues in pathovars of Pseudomonas syringae and P. savastanoiRobert W Jackson, John W Mansfield, Hassan Ammouneh, et al.
Brain : a Journal of Neurology|February 14, 2019
Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosisIna Mexhitaj, Mukanthu H Nyirenda, Rui Li, et al.
Pageof 138